↓ Skip to main content

Correction to: Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID…

Overview of attention for article published in Trials, February 2022
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (56th percentile)

Mentioned by

twitter
3 tweeters

Readers on

mendeley
43 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Correction to: Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol
Published in
Trials, February 2022
DOI 10.1186/s13063-022-06073-7
Pubmed ID
Authors

Francisco Mera-Cordero, Sara Bonet-Monne, Jesús Almeda-Ortega, Ana García-Sangenís, Oriol Cunillera-Puèrtolas, Sara Contreras-Martos, Gemma Alvarez-Muñoz, Ramon Monfà, Marina Balanzó-Joué, Rosa Morros, Betlem Salvador-Gonzalez

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 43 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 14 33%
Student > Ph. D. Student 11 26%
Student > Bachelor 4 9%
Researcher 3 7%
Professor 3 7%
Other 4 9%
Unknown 4 9%
Readers by discipline Count As %
Unspecified 17 40%
Medicine and Dentistry 10 23%
Nursing and Health Professions 6 14%
Psychology 2 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Other 2 5%
Unknown 5 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 May 2022.
All research outputs
#12,767,208
of 21,775,893 outputs
Outputs from Trials
#3,069
of 5,564 outputs
Outputs of similar age
#175,023
of 406,919 outputs
Outputs of similar age from Trials
#1
of 1 outputs
Altmetric has tracked 21,775,893 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,564 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 406,919 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them